Results 171 to 180 of about 23,309 (224)

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence. [PDF]

NPJ Breast Cancer
Khor CC, Ong WS, Lim EH, Chatelut E, Chen S, Muerdter TE, Abraham JE, Sutiman N, Lim JSL, Lee SS, Arellano C, Li Z, Sim KS, Eccles DM, Tapper WJ, Maishman T, Zgheib NK, Winter S, Ganchev B, Dorling L, Guo Q, Caldas C, Earl HM, Hiller L, Dunn J, Ng RCH, Yap YS, Wong M, Wong FY, Wong NS, Ang PCS, Dent R, Krippl P, Langsenlehner U, Langsenlehner T, Tfayli A, Schaeffeler E, Eichelbaum M, Hamann U, Fasching PA, Beckmann MW, Dalenc F, White-Koning M, Brauch HB, Schroth W, Renner W, Schwab M, Thomas F, Chowbay B.   +48 more
europepmc   +1 more source

Pharmacogenomics and Epigenetic Regulation Transforming Pediatric Precision Therapeutics. [PDF]

J Pers Med
Satyam SM, Prabhakar S, Densil T, Mohammed HT, Kumari R, El-Tanani M, Rehman A, Kharoufeh A, Dalbah M, Eltrabishi MTZM.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Decreased in Vivo Clearance of CYP2D6 Substrates by CYP2D6*10 Might Be Caused Not Only by the Low-Expression but Also by Low Affinity of CYP2D6

Archives of Biochemistry and Biophysics, 2000
CYP2D6 exhibits genetic polymorphism with interindividual differences in metabolic activity. We have found a significant influence on the pharmacokinetics of venlafaxine by the CYP2D6*10 allele in a Japanese population. CYP2D6.10, which is translated from CYP2D6*10, has two amino acid substitutions: Pro34 --> Ser and Ser486 --> Thr.
Junichi Azuma, Tsuyoshi Fukuda, Yoshihiko Funae   +2 more
exaly   +3 more sources

The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity

Clinical Pharmacology & Therapeutics, 2021
rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant “enhancer” single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates ...
Jean C, Dinh, Erin C, Boone, Vincent S, Staggs, Robin E, Pearce, Wendy Y, Wang, Roger, Gaedigk, James Steven, Leeder, Andrea, Gaedigk   +7 more
openaire   +2 more sources

Induction of CYP2D6 in pregnancy*

Clinical Pharmacology & Therapeutics, 1997
Expression of the drug-metabolizing enzyme cytochrome P4502D6 (CYP2D6) is predominantly under genetic control, and enzyme-inducing drugs have little influence on its activity. We studied the activity of CYP2D6 during pregnancy. One hundred forty pregnant women were genotyped for CYP2D6.
M, Wadelius, E, Darj, G, Frenne, A, Rane
openaire   +2 more sources